Live-cell FRET imaging-based efficacy prediction of EGFR-TKIs in EGFR L858R-mutant NSCLC

Objectives

Functional assays can assist individualised selection of treatment regimens by evaluating the ex vivo response of tumour cells to anticancer therapeutics. However, the two major strategies used to assess responses to targeted drugs, target-based profiling and phenotypic profiling, have inherent limitations. Target-based profiling does not directly capture downstream cell-fate outcomes, whereas phenotypic profiling provides limited mechanistic information on drug action.